Skip to main content

Research Repository

Advanced Search

Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: Justification for direct measurement?

Sathyapalan, T.; Atkin, S. L.; Kilpatrick, E. S.

Authors

T. Sathyapalan T.Sathyapalan@hull.ac.uk

S. L. Atkin

E. S. Kilpatrick



Abstract

Aim: The benefit of direct, as opposed to calculated, low density lipoprotein - cholesterol (LDL-C) measurement remains unclear. This study compared the biological variability of direct LDL in patients with type 2 diabetes (T2DM) on equivalent doses of the short half- life statin, simvastatin or the longer half- life statin, atorvastatin. Methods: A cross-over study of biological variation of lipids in 26 patients with T2DM taking either simvastatin 40 mg (n = 10) or atorvastatin 10 mg. After 3 months on one statin, fasting lipids were measured on 10 occasions over a 5-week period. The same procedure was then followed on the other statin. The variability of LDL-C was established using a Beckman direct assay. Results: As a group, mean LDL was no different between statins (mean +/- s.d.) (1.69 +/- 0.60 mmol/l simvastatin vs. 1.67 +/- 0.60 mmol/l atorvastatin, p = 0.19). However, in all patients, the intraindividual biological variability of LDL while taking simvastatin was markedly higher than with atorvastatin (average s.d. = 0.17 mmol /l simvastatin vs. 0.01 mmol/l, p < 0.0001). Friedewald calculated LDL variability was no different between statins (average s.d. = 0.34 mmol /l simvastatin vs. 0.21 mmol/l atorvastatin, p = 0.19). Conclusions: In contrast to calculated values, direct measurement revealed LDL to be much more stable (the s.d. being an order of magnitude) in T2DM patients taking atorvastatin rather than simvastatin. This means LDL targets can be consistently met with less lipid monitoring using atorvastatin rather than simvastatin. Direct LDL measurement may therefore have a particular role in monitoring patients on statin treatment.

Citation

Sathyapalan, T., Atkin, S. L., & Kilpatrick, E. S. (2010). Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: Justification for direct measurement?. Diabetes, Obesity and Metabolism, 12(6), 540-544. doi:10.1111/j.1463-1326.2009.01190.x

Journal Article Type Article
Acceptance Date Nov 17, 2009
Online Publication Date Nov 25, 2009
Publication Date Jun 1, 2010
Journal DIABETES OBESITY & METABOLISM
Print ISSN 1462-8902
Electronic ISSN 1463-1326
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 12
Issue 6
Pages 540-544
DOI https://doi.org/10.1111/j.1463-1326.2009.01190.x
Keywords Internal Medicine; Endocrinology, Diabetes and Metabolism; Endocrinology
Public URL https://hull-repository.worktribe.com/output/391596
Publisher URL https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1463-1326.2009.01190.x